Distalmotion secures new capital to drive the global expansion of its Dexter surgical robot

Distalmotion, the Vaud-based medtech behind the Dexter robotic system, has completed a financing round led by Revival Healthcare and the Swiss Entrepreneurs Fund, marking a major step in the company’s commercial growth phase.

Distalmotion, based in Eplalinges (canton of Vaud), is known for its Dexter surgical robot, is best known for its Dexter surgical robot, designed to enhance laparoscopic procedures with robotic precision. Featuring two articulated arms and an intuitive console, Dexter allows surgeons to seamlessly switch between robotic and traditional techniques. Its compatibility with existing laparoscopic systems makes it a versatile tool for minimally invasive procedures in a variety of specialties, including general surgery, gynecology and urology.

Since Dexter’s CE-certified debut in 2022, the robot has been used in more than 1,000 surgeries across Europe, demonstrating its effectiveness and maturity in complex procedures. Hospitals such as Saintes in France have integrated Dexter into their robotic surgery programs to benefit from its advanced capabilities.

This latest round of financing, led by Revival Healthcare and joined by the Swiss Entrepreneurs Fund (SEF), will allow Distalmotion to accelerate its commercial activities. “The proceeds from this investment will allow us to enter our next phase of growth, moving from an engineering to a commercial company,” the company said in its official press release. The SEF, advised by Helvetica Capital, now holds a minority stake in the EPFL spin-off.

Heading towards FDA approval in the USA

As part of its global expansion strategy, Distalmotion has also partnered with Proximie, a healthcare technology platform that digitizes the operating room. Through this partnership, Dexter users will have access to Proximie’s telepresence and data management tools, enabling real-time collaboration and knowledge sharing among surgeons worldwide. By combining Dexter’s robotic precision with Proximie’s cutting-edge technology, the two companies aim to improve surgical outcomes and enhance operating room productivity.

Distalmotion is now seeking FDA approval in the USA, a key milestone as the company transitions into the commercial phase and seeks to revolutionize robotic surgery on a global scale.